Medicare will negotiate drug prices for popular medications like Ozempic and Wegovy, aiming to save billions for taxpayers ...

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

Medicare Part D plans can only cover obesity ... Lilly and its main rival in the obesity-drug race, Denmark's Novo Nordisk (NVO) (DK:NOVO.B), are conducting trials to evaluate GLP-1 drugs as ...

However, if he follows through with imposing tariffs on imports coming from Denmark, it could drive up the already expensive cost of one of America’s fastest-growing obsessions: weight-loss drugs.